Global Trial Accelerators™ is produced by bioaccess® · The First-in-Human CRO →
Global Trial Accelerators™
Global Trial Accelerators™
Accelerate Your Path from First-in-Human to Exit

Hosted by Jesús E. Moreno (Business Development Director, bioaccess®), Global Trial Accelerators™ is a clinical trials podcast for life-sciences founders and innovators in MedTech, Biotech/Biopharma, and Radiopharma, focused on first-in-human (FIH) and early feasibility studies. The show is produced by bioaccess® and was founded by Co-Founder & CEO Julio G. Martinez-Clark.

bioaccess® is a CRO purpose-built for first-in-human (FIH) trials, serving MedTech, Biopharma, and Radiopharma startups. This podcast delivers strategies, regulatory insights, and founder stories to get your technology into humans faster and affordably, with data designed to support FDA and EMA submissions.

Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and founders who have compressed timelines, reduced costs, and generated the clinical evidence investors demand by drawing on on-demand clinical research capability across the Americas.

What You'll Learn:
- Regulatory pathways across Latin America (Colombia, Mexico, Brazil, Chile, Argentina, Panama, Ecuador, El Salvador, Dominican Republic, Paraguay, and more)
- Why ethics approval in 4–8 weeks (vs. 6–12 months in the US/EU) changes the game for startups
- Strategies to generate FIH data that unlocks your next funding round or acquisition
- The Innovation Runway: from prototype to clinical milestones before capital runs out
- Lessons from more than 130 episodes with leaders from seed-stage startups to Fortune 500 MedTech companies
- Decentralized trials, AI-driven recruitment, and post-trial commercialization

Subscribe to unlock your shortcut from first-in-human to exit.

Brought to you by bioaccess®, an FIH-dedicated CRO for healthcare startups. Faster timelines, lower costs. Since 2010.
Nov. 20, 2026

Guillermo Ferrando, CEO at Premium Fertility

Guillermo Ferrando, CEO at Premium Fertility
Global Trial Accelerators™
Guillermo Ferrando, CEO at Premium Fertility

In this episode, we are joined by Guillermo Ferrando Huertas, General Director of the Carlos Simón Foundation for Research in Women's Health and CEO of Premium Fertility, iPremom, and Asherman Therapy.

With a strong background in strategic planning, business development, and healthcare innovation, Guillermo brings extensive experience from leadership roles at Vitrolife Group, Igenomix, Siemens Gamesa, and Bain & Company.

Guillermo shares his perspective on bridging the gap between scientific research and clinical applications, bringing together scientists, clinicians, engineers, and business teams to transform promising discoveries into innovative healthcare solutions.

Discover the importance of strategic leadership, collaboration, and translating scientific advancements into meaningful progress in women's health and reproductive medicine.

Jesus Moreno: to Global Trials Accelerators, the podcast where we dismantle the barriers to clinical innovation and explore the strategies driving the next generation of life-saving therapies. Preeclampsia affects five to eight percent of pregnancies worldwide, standing as the primary cause of maternal and fetal morbidity, much of which is preventable if detected in the first trimester. While the underlying molecular science to identify early risk exists, the far greater operational challenge is translating a decade of academic research into a validated diagnostic that can clear regulatory hurdles in the US and Europe, earn payer reimbursement, and seamlessly integrate into everyday paternal care [00:01:00] Our guest today is the executive leading that exact translation. Guillermo Fernando Huertas is the CEO of IPRA Mom, Valencia-based molecular diagnostic company developing MIRA, a cell-free RNA liquid biopsy platform designed to predict first trimester preeclampsia risks long before clinical symptoms appear. Guillermo trained as an engineer, worked in management consulting, and served as the VP of Strategy and Corporate Development at Vitrolife during its one point two billion euro acquisition of Ingenomics. He later led a research translation at Fundación Carlos Simón before taking the helm at IPRA Mom, which recently closed a fifteen million seed round . To accelerate Mira's international clinical validation and commercial deployment. [00:02:00] Guillermo, welcome to Global Trials Accelerators.

It's a pleasure to have you with us today.

Guillermo Ferrando: Thank you very much, Jesus. It's a pleasure also for me, and thank you for organizing this podca-- th-this podcast. You did a very great summary. Honestly, I'm surprised you covered everything that is relevant for the podcast in a very short period of time. Uh, I see that you have the experience presenting this podcast, and you know how to do it

Jesus Moreno: Appreciate those, uh, kind words, sir. And, the idea is to dive deep and, and have a discussion about how this process unfolds and help our audience understand the technology, the strategy, and, uh, the promise behind this new innovation. Uh, you trained as an engineer and started your career in management consulting. I'm curious to learn what was that catalyst that pulled you away from general corporate strategy and directed you [00:03:00] into reproductive, uh, genetics and med tech in, in Igenomics?

Guillermo Ferrando: It's, it's a great question because my background might not be the, the standard background of the CEO of a biotech startup. So, uh, I choose my, my studies in engineering because they were a very generic field. I always loved science and, and technical degrees, and I studied what is called industrial engineering, a degree in which we cover most of, uh, of the technical topics that affect multiple companies, including, uh, also a brief overview of biotechnology sector, and that allowed me to have a very broad perspective of, of multiple disciplines.

When I was finishing my, my degree and then starting to look at the professional world, trying to, to, to choose a career, [00:04:00] I did something very similar as well. Management consulting, uh, are very intense year of working, but, uh, you learn a lot, a lot of skills, a lot of experience because of the interaction with senior executive and because of the diverse set of projects that you get exposed to.

So I moved into consulting also because I had some friends working in management consulting to still keep my doors open in order to, to be able to be exposed to different fields and professions. And then when I was... A-after a few years, when I was feeling ready to move outside of consulting, when I was feeling that my learning curve had flattened, that I was not learning as much as, as initially I started to look at different companies and different sectors, and then just by pure chance, it was lucky those of opportunities [00:05:00] that come to your life.

There was a position open in-- at the, at the company called Igenomix. So Igenomix, now part of Vitalife Group, is a genetic testing laboratory offering genetic services to reproductive fertility assisted clinics around the world. The position was called Project Manager, and it was created when, when a private equity firm had acquired Igenomix.

The private equity had developed a strategy plan to grow the company, to expand internationally, improve internal operations, launch new tests, eh, improve talent, all the possible levers to, to increase the, the size of the company and, and make it more competitive. And they were looking for somebody with the consulting expertise to-- able to work in, in corporate strategy, but also interested in joining the, the [00:06:00] company that was, of course, present in the biotechnology industry.

And I need to say that always I, I love biology. It was my maybe second choice after engineering. And I, I, I did the interviews, the selection process, got accepted, and I found it a very interesting sector. So I have done multiple training since then on different versions of biology. I learned a lot from my colleagues.

Um, and this is the s-- the explanation of how I ended in Igenomix. And then how I ended in Ipromom is also maybe for a second question.

Jesus Moreno: Yes, uh, definitely want to get into that, uh, further, uh, down the line of, of this, uh, conversation. But right now I am hearing you talk about that acquisition and it, it, it was roughly 1.2 billion [00:07:00] euro acquisition, uh, for Igenomics. Um, and you being in the forefront of that process, I, I'm sure that gave you a lot of experience and insight into, um, how acquisit- from the acquisition side of the table, um,

Guillermo Ferrando: Yes

Jesus Moreno: buyers actually evaluate the commercial value of translational science versus the pure academics potential that, this, uh, initiatives, this research ideas, this technologies So can you walk us, uh, through that process? How does a public buyer look at a translational opportunity and, and how does that contrast from the academic, uh, realm or, or lens?

Guillermo Ferrando: Yes. It's, it's a great question. So Igenomix was a unicorn, more than one billion, sold to the [00:08:00] Swiss group. And I need first to say that public buyers or, or industrial buyers that are called sometimes in the jargon, strategic buyers, that they have an interest into holding the company integrate with the current operations.

They are looking, uh, they are evaluating the, the transactions using financial criteria. So they want to acquire a business that has a defensible position of revenue, recurrent sales with good margins, and that can provide value to the shareholders. And this is how we need to connect science with economical return.

So good science that can be translated creates innovations, either products or services that are adopted by physicians and by patients to improve medical practice. And in reward for the inver-- for the investment, the company that is offering those solutions obtains a [00:09:00] margin. They, they, they-- it, it drives the sales and, and if they are offering a very high quality product with lot of value added, the margin is higher.

So Vitolife, the ac- the acquirer, looked at Igenomix, and one of the value drivers of Igenomix was the scientific differentiation. There were two executive at Igenomix, the CEO and at the same level, the chief scientific officer. The chief scientific officer was called Professor Carlos Simon, the founder of Igenomix, and the CEO is, was a businessman called David Jimenez.

They worked hand-in-hand always, and they, they had the vision of using high quality research to improve medical practice. And that vision, that positioning was making Igenomix different from other genetic testing laboratories. Was also the driver of, of why [00:10:00] some fertility clinics used Igenomix as supplier, was the key differentiation criteria.

So this is how, how it was connected. Research that can be translated into practical application in the real world, from bench side to the bedside of the patient was, was driving the growth. Initially, Igenomix when, when it started, was making around ninety-five percent of sales from commodity products, from genetic tests that were offered by multiple companies.

And when it was acquired by Vitolife, half of the revenue was made from tests created by Igenomix innovations, and half of the other revenue was coming from genetic tests offered by other different companies.

Jesus Moreno: I see. And so being in that position, that, uh, VP [00:11:00] strategy corporate, uh, development position, uh, you then transition to Fundación Carlos Simón to oversee the research and-- of the trans-translational technology? Uh, I'm curious to explore a little bit, what did you see missing in, in that corporate world, uh, that made you want to step back to the very beginning of the translational pipeline and lead a startup as a CEO?

Guillermo Ferrando: Wonderful question. I, I, I even ask this a lot of times to myself when I got the offer from Carlos Simon to, to lead the foundation that he has started. One aspect is, uh, politics. So big corporates that have multiple layers of, of managers and different sites, headquarters in one country or in another, require a lot of time [00:12:00] spent in, in politics.

And not just fighting, but also driving human relationships, agreeing with others how to split tasks, and not really doing the, the actual work, but internal reporting. And I was spending most of my time on that. By moving to a smaller organization, Carlos Simon Foundation, that is promoting the creation of startups like iPromot to, to translate to the patient world innovations, I want to ha- to, to, to move closer to the real action.

Jesus Moreno: Угу

Guillermo Ferrando: So that's the, the main driver of change. The second is that I had a wonderful experience with Carlos Simon. I was, uh, amazed by the experience that he... by the capability and the capacity to move forward, to have a vision on how to change the medical practice in reproduction. He's an expert in, in reproduction.

And then to move that forward, engage stakeholders and other, uh, parties, [00:13:00] ensure the commitment, and to, to create something from, from a pure idea. Carlos Simon is, is, is now my-- is my, is my boss, so he works in Carlos Simon Foundation. He's part of the shareholders of iPromot, and I keep learning a lot from him.

He's a mentor to me. Also, David Jimenez, the, the CEO, wonderful businessman of Igenomix, he's present in, in Founda- in Carlos Simon Foundation as a trustee, somebody part of the, of the trustees that is giving private funds to the foundation and is still involved providing strategic guidance. So to summarize,

Jesus Moreno: community

Guillermo Ferrando: yeah, exactly.

Very close. To summarize, the first was to move closer to the real action, entrepreneurship, uh, mindset. And the second was, uh, the community, be closer to, to my [00:14:00] mentors

Jesus Moreno: I see. And what was the hardest operational adjustment for you moving from a corporate strategy public company to, running a lean high velocity, molecular diagnostic startup?

Guillermo Ferrando: I will say that the lack of processes, systems, and tools that normally you assume that they have been always there, uh, but, uh, we need to create the basics. Just commenting on a software to register holidays request or, or the timesheet, ERP, CRM, uh, file sharing systems, and not just on the side of IT or software programs, but also on the culture of the working processes.

So starting an organization from scratch requires the, the, the management not only to develop the product and to sell it and to make it in an, uh, at an affordable [00:15:00] cost, but also to create an organization that can work standalone and, and fulfill its obligations. And I'm referring to the functions like finance, legal, IT, HR.

Those administrative functions were totally missing when I moved to Carlos Simon Foundation

Jesus Moreno: I see. So the, yeah, the backbone of admin,

Guillermo Ferrando: Yes, exactly

Jesus Moreno: I see. Okay. Guillermo, I would like to now move, uh, into a little bit more of the scientific evidence and, and explore the technology itself. So, um, Mira is built on the PREMMOM study, a prospective cohort of over 26,000 samples linked to 10,000 pregnancies. You recently raised a 15 million seed round to, to fund the clinical [00:16:00] validation. Now, what does this new capital need to demonstrate to regulatory and payers that academic study that, that uh, s- that sizable academic study, did not?

Guillermo Ferrando: Yeah. I-- thanks for, for these questions. It gives me the opportunity to explain that although the, the innovation called MiRA builds on the study that you explained, this started a lot of time ago when the scientific director, Dr. Tamara Garride-- uh, scientific director, Dr. Tamara Garrido, started the PhD thesis on the origin of preeclampsia.

So she started doing research on why preeclampsia was happening. For the audience, preeclampsia is a pregnancy complication [00:17:00] that can appear in the last semester of the pregnancy unexpected, with the symptoms of high blood pressure and organ damage that can require the immediate, uh, delivery of the baby, and in the most fatal cases, it can result on the death of both the mother and the fetus, something that we want to avoid, of course.

And, and Tamara started... And, and the problem basically of preeclampsia is not only the negative consequence of preeclampsia, but that it, it is-- it cannot be detected easily until there are symptoms, until it is present, and is the precedent of eclampsia that is much more severe. So Tamara was, was doing research on the origin, and she found that during the invasion of the embryo inside the uterus and the creation of the soil The process [00:18:00] that is called decidualization is not w- is not being performed well in the cases of women with preeclampsia.

There is something called decidualization resistance, and that biological event, decidualization resistance, leaves a footprint at the blood of the mother. It's a footprint that can be detected by analyzing the cell-free RNA. RNA is, is the transcription of DNA. We normally look at DNA when we do genetic testing, and at this case, we are moving one step forward looking at RNA.

So Maira is by, by measuring the RNA and using the learning from the PremOm study that we were taking samples from women that were pregnant in the first, second and third trimester, and then for the women that had [00:19:00] preeclampsia and studying what could be detected in the blood obtained in the first trimester.

Maira is able to detect very early the risk of preeclampsia, because preeclampsia starts at the origin of pregnancy much earlier than the diagnostic. Maira is looking at the biology. Um, and you go-- you asked me, thanks for ask. Um, I, I spent a lot of time commenting on scientific evidence, but you asked me on the use of the seed round.

So we have already the regulatory approval in Europe, but we offer the product as a service using the, uh, the framework of LDT, laboratory developed test, because the same test is developed and operated by Maira. iPremOm is working on the CE mark approval of the software that will allow us to, [00:20:00] to license the technology to other laboratories.

And for the future, we want to expand to US. It's a very important market for us due to the prevalence of preeclampsia and the size of the market and also the, the, the willingness from doctors to adopt new innovations. And we will very likely required to do a clinical study in American population. And with that evidence, we will submit it to the FDA, enough safety and efficacy, um, evidence to obtain the market authorization.

So in a nutshell, for the regulatory body in US, we need to demonstrate still safety and efficacy. Of course, the data that exists in European population is, is beneficial, is a positive argument, but we will need to gather data in American population

Jesus Moreno: Understood. And thank you for that explanation, [00:21:00] Guillermo. That gives us a full understanding of the context. Diving a little bit deeper into that regulatory strategy, targeting both Europe and US, uh, almost simus-simultaneously, it's, it's a daunting task, uh, submitting in parallel and dealing with both agencies. What does it take operationally to run a multi-jurisdictional clinical trial and regulatory process, uh, filing in, in both, uh, regions? Um,

Guillermo Ferrando: Yeah

Jesus Moreno: and how does that affect the timeline, and how, how do you keep one, one, regulatory process from becoming a bottleneck to the other region's regulatory process?

Guillermo Ferrando: Så

Carlos Simon Foundation is an ecosystem for the research, but also for the creation of [00:22:00] startups acting as a venture builder. And there is an internal team specialized in the definition, approval, monitoring, and closing of clinical studies, an internal CRO. So that solves one of the bottlenecks. We consider clinical studies as an strategic activity, and that's the reason why it was insourced and managed by internal team.

Of course, we, we rely on advisor with a specific knowledge or when the workload hits a peak. But normally, we try to perform the management or to run the clinical study in-house. The second, uh, point to avoid this bottleneck and to organize everything is that we have performed already the PRIMOM study.

We have closed it, and there is a second study called i-Prognostic that has finished recruitment already, and we are [00:23:00] waiting for all the women to deliver the baby to record the obstetrical outcome. And once we are ready with that, we will move with the US clinical study. So in summary, we do a sequential phasing of the different studies in order to, to avoid problems and to avoid not being able to manage them with our internal team.

And the third that I would say is that regulatory team works very closely with the clinical development team. They sit together. They need to speak the same language, be very close, and sometimes use very similar documents. The initial documents describing Mira that are submitted to the ethical committee, for example, the information that is there is already also being compiled at the technical documentation that will be submitted for the market authorization.

So those company-- those two teams, by working very closely, they can leverage a lot of [00:24:00] synergies

Jesus Moreno: Of course. And many European med tech and diagnostic founders struggle when, when expanding into the US. Uh, from your vantage point, what is the most critical strategic mistake a EU founder makes when attempting to execute a simultaneous US-EU clinical validation, uh,

Guillermo Ferrando: Well

Jesus Moreno: objective of expin- expanding to the US market?

Guillermo Ferrando: We are still not there, so, so I, I, I want to give my best possible answer to your question. But as a, a disclaimer, please take note that I'm speaking on the plans and what I have learned from the others. I think that, uh, somebody needs to be local on the ground. So a European startup cannot manage everything from abroad, offline or some traveling.[00:25:00] 

Um, at least one employee needs to be present in US, ideally with experience in previous entrepreneurship in, in biotechnology field, in clinical studies. The, the more similar, the better. And I will, I will rely on that. And second is study very well the existing FDA regulation and the existing European regulation.

So once that we submit a document or once we ask a question We, we succeed in the terms that we get what we were aiming for

Jesus Moreno: Boots on the ground and a clear plan

Guillermo Ferrando: Yes, exactly

Jesus Moreno: Угу Wonderful. Uh, now talking a little bit into-- looking into the future even further, [00:26:00] uh, underneath the MiRA RNA liquid biopsy engine, is your lead indicator, but the technology has a broader application in tracking gestational complications. How much of Ipermom's long-term, uh, vision, uh, values in, in preeclampsia specifically versus cf, uh, RNA platform?

Guillermo Ferrando: Great question, Jesus. And this is true. We started with preeclampsia. To solve the problem of preeclampsia risk detection, we had to develop a technology able to detect the footprint of biology events, analyze it, and deliver a risk assessment. And later, we found that this same technology that we ha-had-- we had [00:27:00] to de-to, to develop can be used to do the same for other pregnancy complications.

The clinical study that we have done, PREMMOM, collects samples from almost ten thousand women that have developed every possible pregnancy complication in the world. It's a huge cohort with representation of spontaneous preterm birth, restriction of intrauterine growth restriction, gestational diabetes, and many more.

And those two-- tho-those, those pregnancy complication also happen before or the, the origin is in events that happen before they can be detected if we are only looking at the symptoms. So we are going to use the same principle, look at the [00:28:00] origin in the biology, try to find the root cause. There are-- There is wonderful science that is published on what may be the cause of, of those complications, and we want, we want to use the, the technology.

So our vision is to be the global leader of prenatal com, uh, diagnostics, helping physicians to take the right decisions at the right time because we believe that earlier detection means better care for the mother that is pregnant

Jesus Moreno: And better outcomes, absolutely.

Guillermo Ferrando: better outcomes.

Jesus Moreno: that, in that process of, uh... Well, MIRA is already in, in clinical use through IPRA

Guillermo Ferrando: Yes

Jesus Moreno: in Spain, as, as you've mentioned previously. there's nothing-- There's no better teacher than getting a [00:29:00] brush, a, a, a firsthand with the real world. what are your insights as to how OBGYN, uh, professionals integrate first trimester molecular screening into their daily work, through this s- th- through this first real world rollout of, of the technology?

Guillermo Ferrando: We-- I will say that startups and companies in general, instead of pushing innovations to the market, they need to listen what the client needs. So what we did from the beginning was to listen a lot how physicians and general OBGYN doctors treat and deal with risk, uh, pregnancies that are at risk or with gene-- or what is the daily practice.

And we found that some of them are using methods to detect preeclampsia [00:30:00] based on the symptoms, and we then convince them that they can detect the preeclampsia earlier by looking at the origin and not the symptoms with higher accuracy. We found that, uh, normally the traditional method have a very high rate of false positive.

In order to not miss any case of preeclampsia, the current methods give a lot of false positive. So many women are over-medicated with aspirin or other, uh, treatments, other therapies, or they are treated as high-risk pregnancies even when the risk is not low. And then regarding to the, to the operation and the logistics, we tried, uh, to mimic an existing molecular test in a very similar window called non-invasive prenatal test.

It's a test [00:31:00] that is analyzing the DNA, the, the blood of the mother to sequence the DNA of the fetus to detect chromosomal abnormalities, to detect, uh, problems of genetic origin. And i- the blood of the mother is taken in the same period of window between the, the weeks ten to twelve, the same period of Maira.

And we try to

Gain from though-- from gain the established operational procedure, the same pr-- the same procedure that is present thanks to the adoption of such test

So, so to summarize, what is important is to listen to the client, listen to the user, instead of pushing the innovation. Adapt our operational secret and procedure to what is possible at hospital and clinics, and communicate the innovation in a way that we can demonstrate the [00:32:00] benefits versus the current state of the art

Jesus Moreno: Wonderful. Guillermo, we've, we've talked about the background, the history, the scientific basis for the technology, and a little bit about the regulatory strategy. I would like to, uh, now focus on what some consider the holy grail of this, uh, med tech, uh, rollout process, which is reimbursement. When, when a translational technology achieves that reimbursement, uh, status, it, it can be said that it's been successfully rolled out into, into the market.

So accuracy does not-- alone does not get you there. There's no guarantee of success. Uh, payers and health systems must be convinced [00:33:00] that to, um, the, the technology is worth the reimbursement to, to guarantee access to it. How are you, um, in Myra, mm,

Guillermo Ferrando: We are working on it

Jesus Moreno: yeah, working on, on getting to that status?

Guillermo Ferrando: Well and true. So we are working on reimbursement. Still, we are not reimbursed either by public payers, very widely expo-- uh, very present in, in Europe. Normally in Spain, the National Security System covers a lot of medical technologies or in private insurance also present. Still not, but we are having initial conversations, and the thing that they need to see is the cost-benefit analysis, also called health economics or with other terms, but basically, uh, an analysis of the [00:34:00] additional cost of doing MIRA, not just by paying for the test, but also but what extra activities is required either by the doctor, nurse, or any other person in the hospital, and what are the benefits.

Benefits in terms of quality of life for the patient, but also benefits in terms of cost for the health system. So the main benefit of detecting earlier preeclampsia is to avoid intensive care units for both the mother and the fetus. That when suddenly preeclampsia strikes, they need to deliver the baby without prior preparation.

They spend two weeks in intensive care unit, and most of the time is the fetus, and that has a, a huge cost. And there is, uh, also a, an impact on the quality of life of the mother. Preeclampsia have lifelong consequences. Payers don't r- pay much more [00:35:00] attention at the economical consequences. It's true, but they also pay attention to the, to the improvement of the quality of life.

So that health economic analysis is an internal study done internally at Ipremom that we refine as we gain more experience, and we have conversations with insurers And you, you summarized it very well, Jesus. Payers are not only looking at accuracy, they are looking at a cost benefit. So it needs to be very clear how the innovation provides ben-benefit and positive value to the healthcare system

Jesus Moreno: Wonderful. Thank you for that, Guillermo. And in closing, looking forward five years out, how do you see the first trimester molecular screening, uh, fundamentally being reshaped, uh, as a standard of care in maternal health worldwide? What do you think [00:36:00] it's gonna happen in this space in the next five years?

Guillermo Ferrando: Definitely that is going to happen, Jesus, and it's not only because iPreMom is, is laun- uh, has launched the test and is working to evolve it. It's also because of multiple, uh, trends as precision medicine. That means that doctors are trying to find unique information on the patient instead of treating with general guidelines.

The same for every women. Is the, the advancement in maternal care and also the, the awareness and the, and the importance that is now given to prevent problems during pregnancy. That is on the demand side. There is a huge demand for this type of medical technology. And on the supply side, iPreMom is working to make this a reality by first deploying Mira preeclampsia test to detect early the risk of preeclampsia, and later to [00:37:00] expand that offering into a single test with a single blot of...

a single draw of blood can detect the risk of multiple pregnancy complications and enable the prevention of those. We are working to make this vision a reality, a reality in which women do no longer fear for their pregnancy

Jesus Moreno: That's a lofty goal and a huge

Guillermo Ferrando: We strike to the moon

Jesus Moreno: Yes. Yes, sir, and we will get there.

Guillermo Ferrando: We, we want to arrive to the moon. Maybe we don't get to the moon, but, uh, that's our vision, that's our goal. And, you know, every possible CEO that you might interview in the podcast, they want to change the, the state of the art. They want to, to improve the life of the patients. We are not here only because we want to have an economical return on, on our entrepreneurship ventures.[00:38:00] 

And the investors that are with us also, yes, of course, they have-- they want to, to have a return on the investment that they have doi- been doing, but they also want to see how the medical practice change, how patients are be-better treated, and how women's health gets improved

Jesus Moreno: Absolutely. Guillermo, the core takeaway today is, is vital, I believe. Discovering a powerful molecule biomarker is only the first step. Translating that discovery into a global standard of care requires disciplined execution across tracks, rigorous health economic planning, and seamless clinical workflow integration. Thank you for sharing your strategy, vision, and insights with us today

Guillermo Ferrando: Thank you very much, Jesus. It has been a pleasure, and thanks for doing this initiative. Is, is wonderful to have to be inspired by [00:39:00] the experience of executive in the industry and to learn from others. Thank you very much for this effort

Jesus Moreno: I completely agree with that. And to our audience, thank you for tuning into Global Trials Accelerators. If this episode provided actionable insights for you on your regulatory or commercial roadmap, share it with a colleague, a founder, or a friend. Subscribe where you listen to our podcast, and we'll see you on our next episode. Until next time, keep accelerating